Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
- PMID: 23104868
- PMCID: "V体育官网入口" PMC3717947
- DOI: 10.18632/oncotarget.689
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Abstract
The molecular foundations of lower-grade gliomas (LGGs)-astrocytoma, oligodendroglioma, and oligoastrocytoma-remain less well characterized than those of their fully malignant counterpart, glioblastoma. Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) likely represent initiating pathogenic events. However, while IDH mutations appear to dramatically alter cellular epigenomic landscapes, definitive downstream transformative mechanisms have not been characterized. It remains likely, therefore, that additional genomic abnormalities collaborate with IDH mutation to drive oncogenesis in LGG. We performed whole exome sequencing in 4 LGGs, followed by focused resequencing in an additional 28, and found a high incidence of mutations in the ATRX gene (α thalassemia/mental retardation syndrome X-linked). ATRX forms a core component of a chromatin remodeling complex active in telomere biology. Mutations in ATRX have been identified in multiple tumor types and appear to cause alternative lengthening of telomeres (ALT), a presumed precursor to genomic instability. In our samples, ATRX mutation was entirely restricted to IDH-mutant tumors, closely correlated with TP53 mutation and astrocytic differentiation, and mutually exclusive with 1p/19q codeletion, the molecular hallmark of oligodendroglioma. Moreover, ATRX mutation was highly enriched in tumors of so-called early progenitor-like transcriptional subclass (~85%), which our prior work has linked to specific cells of origin in the forebrain subventricular zone VSports手机版. Finally, ATRX mutation correlated with ALT, providing a mechanistic link to genomic instability. In summary, our findings both identify ATRX mutation as a defining molecular determinant for a large subset of IDH-mutant gliomas and have direct implications on pathogenic mechanisms across the wide spectrum of LGGs. .
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Wen PY, Kesari S. Malignant Gliomas in Adults. The New England journal of medicine. 2008;359:492–507. - PubMed
-
- Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522. - PMC - PubMed
-
- Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub TR, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2009;17:98–110. - PMC - PubMed
Publication types
- V体育ios版 - Actions
MeSH terms
- "V体育ios版" Actions
- Actions (VSports在线直播)
- Actions (V体育2025版)
- Actions (VSports在线直播)
- "V体育平台登录" Actions
- "VSports手机版" Actions
- V体育2025版 - Actions
- Actions (V体育安卓版)
- VSports手机版 - Actions
- Actions (VSports app下载)
Substances
- Actions (V体育官网入口)
- V体育安卓版 - Actions
- Actions (V体育官网)
- VSports - Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
